Month: February 2020

Adtec Healthcare's new project with Hull York Medical School testing gas plasma on Osteomyelitis bone infections.

We are excited to announce the study “Gas Plasma for the Prevention and Management of Osteomyelitis Biofilms” has now begun at the Hull York Medical School. The study led by Dr Angela Oates and funded by the National Biofilms Innovation Centre will seek to test the efficacy of our gas plasma system on osteomyelitis bone infections using our PlasmaTact device. This project will develop a novel laboratory testing model to evaluate and optimise plasma treatment for osteomyelitis biofilm infections.

We have already demonstrated that our gas plasma medical device, the Adtec SteriPlas, has proven antibacterial efficacy and accelerated healing in problematic and non-healing wounds with strong evidence collected from our extensive library of clinical trials and publications. This includes diabetic foot ulcers which are often complicated by biofilm. Over the course of its existence it has shown that no side effects have been reported which offers patients a safe and reliable treatment option. It has also shown that a 2-minute treatment time is sufficient to achieve exceptional results and that it is also a broad spectrum antibacterial with the ability to kill a wide range of Gram-negative and Gram-positive bacterial superinfections.

The PlasmaTact utilizes the same gas plasma technology from the Adtec SteriPlas. The main difference between the two devices is that the PlasmaTact offers a smaller handheld style treatment area of 1cm² (vs 12cm² with the SteriPlas) and offers users the ability to change the power output settings (vs the fixed settings with the SteriPlas).

Osteomyelitis (OM) is biofilm infection of the bone and is a common and costly complication in diabetic foot ulcer (DFU) patients often resulting in amputations. Long-term antimicrobial therapy is widely used as a primary treatment for OM or as an adjunct to surgical approaches however, there is a failure rate of up to 35% and an associated increasing prevalence of antimicrobial resistance. There is an urgent clinical need to develop alternative non-antimicrobial approaches to treat infections, and currently there is a lack of credible alternatives in the market for the treatment of OM.

Evaluating the efficacy of gas plasma in OM represents unique challenges as both the biofilm growth and physical characteristics of OM bone will affect the delivery and activity of the plasma. In vitro biofilm model systems offer a means by which rapid, costs effective and standardised evaluation of anti-biofilm treatments can be undertaken.

The PATROL project is a new and exciting collaborative project between Adtec Healthcare and Dr Angela Oates of the University of Hull Wound Healing Group which is supported by NBIC PoC Award. The overall aim of this project is to develop an osteomyelitis biofilm infection model to support the optimisation and evaluation of a cold plasma technology for the management and prevention of OM.

This collaborative project represents the first phase of the novel utilisation of Adtec SteriPlas to treat OM or as an adjunct current therapy. Successful translation of this technology to treat OM will reduce antimicrobial usage and associated OM amputations, reducing NHS costs and ultimately improving patient outcomes.

#osteomyelitis #biofilm #boneinfection #infection #antimicrobial #antimicrobialresistance #amputation #plasma #gasplasma #coldplasma #kaltesplasma #NBIC #universityofhull #podiatry #diabeticfootulcer #diabeticfoot #diabetes #hullyorkmedicalschool

by Adtec Healthcare